VeriSign, Inc.
VRSNVeriSign, Inc.'s balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup.
The sharpest disagreement: the engine is strong, but at the 80th percentile of its own range you are paying full price for it.
The price is topping out (11 weeks in) while the P/E sits at the 80th percentile of its own 5-year range. But the balance sheet is under water: net worth is negative, so shareholders sit behind everyone the company owes. What settles it: whether the business can earn its way back to positive equity before dilution or restructuring gets there first.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
VeriSign, Inc. trades at $298, losing momentum at the top and 11 weeks into that stage. That is +13.4% against its own 200-day average. It sits at 88% of a 52-week range of $216 to $310. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is losing momentum at the top — week 11 of stage 3. At $298 it trades +13.4% versus its 200-day average and sits at 88% of its 52-week range ($216–$310).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +249% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
VeriSign, Inc. trades at 32.3× P/E, at the pricey end of its own range (80th percentile). Its long-run median P/E is 28.7×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 32.3× is at the pricey end of its own range (80th percentile), against a long-run median of 28.7× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +10.1% against a +5.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +14.1%/yr price move, ~+10.9%/yr came from earnings growth and ~+3.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
VeriSign, Inc. reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but no return curve is held to confirm the Consistent bar. The read is built from 12 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
The return-on-capital curve is not shown — net worth is negative, so a return on capital is not a meaningful number in any basis. This is a distressed balance sheet, and the stage is read from the growth curves alone.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +6.4% | +5.3% | — | — |
| Profit | +5.1% | +7.4% | — | — |
| EPS | +10.1% | +12.2% | — | — |
| Stock price | +5.7% | +14.1% | +6.4% | +14.5% |
4-Factor Sector Score
37.0/100 — rank 24 of 28 in Software - Infrastructure · 81% evidence confidence
VeriSign, Inc. scores 37.0 out of 100 against the 28 companies it is compared with in Software - Infrastructure, ranking 24. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 10.5 + 10.2 + 7.6 + 8.7 = 37. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
VeriSign, Inc. reported $0.4 B of revenue in the Jun 26 quarter, +4.9% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 5.7% a year. The last full year, FY25, came in at $1.7 B. The last four reported quarters add to $1.7 B.
FY25 revenue came in at $1.7 B (+6.4% on the year), capping 4 years at 5.7% compound. The latest quarter (Jun 26) printed $0.4 B, +4.9% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +6.9% growth against the decade's 5.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.9% over the last 4 quarters against +5.7%/yr over the last 8 — stabilising; TTM profit +6.3% vs +0.6%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
VeriSign, Inc.'s operating margin is 69.8% in the Jun 26 quarter, +1.5 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 65.4% to 67.9%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 69.8%, +1.5 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 65.4%–67.9%.
Why the margin moved: operating margin went +1.5 pp year on year while gross margin went +0.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
VeriSign, Inc. earned $0.2 B of net profit in the Jun 26 quarter, +4.8% year on year. It is the 6th consecutive quarter of growth. Full-year FY25 profit was $0.8 B. The 4-year compound rate is 1.6%. That is 51.2% of the quarter's revenue. The same quarter a year earlier earned $0.2 B.
Jun 26 profit was $0.2 B, +4.8% year on year — the 6th consecutive quarter of growth. On the full year, FY25 printed $0.8 B (+5.1%), and the 4-year compound rate is 1.6%.
Why profit moved: revenue contributed +4.9% and the margin +1.5 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +6.3% vs revenue +6.9%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 116% of VeriSign, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.1 B of operating cash against $0.8 B of profit. After $0.0 B of capital spending, $1.1 B was left as free cash.
FY25: operating cash of $1.1 B against reported profit of $0.8 B, leaving free cash of $1.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 116% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
VeriSign, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
VeriSign, Inc. earns a ROE of −39% in FY25. That is up from a trough of −62% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 50.0% net margin on 1.25× asset turns.
FY25 ROE is −39%, recovered from a FY21 trough of −62% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 50.0% net margin × 1.25× asset turns × −0.62× balance-sheet leverage ≈ −38.8% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
VeriSign, Inc. paid $3.16 per share over the last four reported quarters. The most recent declaration was $0.81 for Jun 26. Against the current price of $298 that is a trailing yield of 1.06%, measured on dividends already paid rather than on a forecast.
VeriSign, Inc. paid $3.16 per share across the last four reported quarters, most recently $0.81 for Jun 26. Against the current price of $298 the trailing twelve months work out to 1.06% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
VeriSign, Inc.'s net worth is negative — it owes more than it owns — so a debt-to-equity ratio is not meaningful here. On the annual view that ratio went from −1.42 in FY21 to −0.84 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $2.3 B against shareholder equity of $−2.3 B — a debt-to-equity of −1.04. On the annual view, debt-to-equity went from −1.42 (FY21) to −0.84 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.9% of VeriSign, Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 2.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.9% of the float is sold short, and at typical trading volumes it would take about 2.2 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
VeriSign, Inc.: the Z-score reads −2.68. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of −2.68 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads −2.68.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Palantir Technologies Inc.PLTR | 69.6/100Favorable setup71% evidence | BREAKING OUT | 30.0/35 Revenue 78.8% · PAT 100% · OPM change 20.3 pp 83% evidence | 19.9/25 ROCE 26% · OPM 47.1% 76% evidence | 9.2/20 P/E 92.7× · PEG — 15% evidence | 10.5/20 RS sector -12% · RS bench 4.1% · 1Y -4.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 19.9 + 9.2 + 10.5 = 69.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Corpay, Inc.CPAY | 64.2/100Mixed-positive evidence81% evidence | LEADER | 22.6/35 Revenue 20.4% · PAT 8% · OPM change 3.4 pp 83% evidence | 20.5/25 ROCE 21.2% · OPM 46.9% 76% evidence | 11.3/20 P/E 19.2× · PEG 1.65 65% evidence | 9.8/20 RS sector -3.6% · RS bench 14.1% · 1Y 33.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20.5 + 11.3 + 9.8 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Microsoft CorporationMSFT | 63.8/100Mixed-positive evidence81% evidence | BREAKING OUT | 18.4/35 Revenue 17.8% · PAT 31.3% · OPM change 0.2 pp 83% evidence | 21.2/25 ROCE 26.3% · OPM 45.1% 76% evidence | 15.3/20 P/E 20.7× · PEG 0.65 65% evidence | 8.9/20 RS sector -13.1% · RS bench 2.7% · 1Y -5.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 21.2 + 15.3 + 8.9 = 63.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4NetApp, Inc.NTAP | 60.0/100Mixed-positive evidence81% evidence | LEADER | 19.1/35 Revenue 5.4% · PAT 7.6% · OPM change 7.2 pp 83% evidence | 15.3/25 ROCE 8.3% · OPM 27.3% 76% evidence | 12.5/20 P/E 17.1× · PEG 1.43 65% evidence | 13.1/20 RS sector 18.1% · RS bench 38% · 1Y 53%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 15.3 + 12.5 + 13.1 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Okta, Inc.OKTA | 59.2/100Mixed-positive evidence71% evidence | LEADER | 20.4/35 Revenue 11.8% · PAT 90% · OPM change 1.6 pp 83% evidence | 9.4/25 ROCE 2.4% · OPM 7.3% 76% evidence | 9.5/20 P/E 52.7× · PEG — 15% evidence | 19.9/20 RS sector 48.3% · RS bench 72.9% · 1Y 101.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 9.4 + 9.5 + 19.9 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Fortinet, Inc.FTNT | 57.8/100Mixed-positive evidence81% evidence | LEADER | 22.8/35 Revenue 18.8% · PAT 9.3% · OPM change 5.6 pp 83% evidence | 16.9/25 ROCE 11.6% · OPM 33.7% 76% evidence | 4.4/20 P/E 54.1× · PEG 4.11 65% evidence | 13.7/20 RS sector 28.9% · RS bench 50.5% · 1Y 104%10 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 16.9 + 4.4 + 13.7 = 57.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Rubrik, Inc.RBRK | 57.0/100Mixed-positive evidence61% evidence | LEADER | 24.9/35 Revenue 45.9% · PAT — · OPM change 19.8 pp 62% evidence | 3.8/25 ROCE -5.3% · OPM -13.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.3/20 RS sector 18.5% · RS bench 38.6% · 1Y 30.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 3.8 + 10 + 18.3 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nutanix, Inc.NTNX | 56.1/100Mixed-positive evidence71% evidence | BREAKING OUT | 19.6/35 Revenue -1.9% · PAT 100% · OPM change 5.2 pp 83% evidence | 11.0/25 ROCE 3.7% · OPM 19.3% 76% evidence | 9.6/20 P/E 43× · PEG — 15% evidence | 15.9/20 RS sector 3.9% · RS bench 21.6% · 1Y -10.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 11 + 9.6 + 15.9 = 56.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9CrowdStrike Holdings, Inc.CRWD | 54.9/100Mixed-positive evidence67% evidence | LEADER | 23.1/35 Revenue 24.3% · PAT — · OPM change 3.4 pp 71% evidence | 5.3/25 ROCE -1.6% · OPM -2.3% 76% evidence | 8.5/20 P/E 3324.4× · PEG — 15% evidence | 18.0/20 RS sector 36.9% · RS bench 59.6% · 1Y 92.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 5.3 + 8.5 + 18 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GoDaddy Inc.GDDY | 53.6/100Thin evidence · provisional56% evidence | BREAKING OUT | 20.7/35 Revenue — · PAT — · OPM change 3.8 pp 39% evidence | 14.7/25 ROCE 6.8% · OPM 24.5% 76% evidence | 11.4/20 P/E 12.6× · PEG — 15% evidence | 6.8/20 RS sector -23.4% · RS bench -9.4% · 1Y -31.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 14.7 + 11.4 + 6.8 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Gen Digital Inc.GEN | 52.7/100Mixed-positive evidence71% evidence | BREAKING OUT | 17.7/35 Revenue 27.1% · PAT 51.3% · OPM change -6.4 pp 53% evidence | 15.3/25 ROCE 6.3% · OPM 62.6% 76% evidence | 8.0/20 P/E 12× · PEG 2.71 65% evidence | 11.7/20 RS sector -3.6% · RS bench 13.5% · 1Y 5.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 15.3 + 8 + 11.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Oracle CorporationORCL | 51.5/100Mixed-positive evidence85% evidence | BASING | 19.9/35 Revenue 21.6% · PAT 50.6% · OPM change 3.9 pp 95% evidence | 15.5/25 ROCE 9.6% · OPM 35.3% 76% evidence | 15.6/20 P/E 22.9× · PEG 0.48 65% evidence | 0.5/20 RS sector -38.5% · RS bench -27.3% · 1Y -53.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 15.5 + 15.6 + 0.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13F5, Inc.FFIV | 50.3/100Mixed-positive evidence81% evidence | TURNING | 14.5/35 Revenue 9.4% · PAT 8.8% · OPM change -0.6 pp 83% evidence | 18.3/25 ROCE 16.3% · OPM 24.6% 76% evidence | 5.7/20 P/E 32.3× · PEG 3.03 65% evidence | 11.8/20 RS sector 4.8% · RS bench 23.4% · 1Y 28.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 18.3 + 5.7 + 11.8 = 50.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Toast, Inc.TOST | 50.1/100Thin evidence · provisional56% evidence | BREAKING OUT | 22.5/35 Revenue 23.4% · PAT 100% · OPM change 3.5 pp 53% evidence | 10.7/25 ROCE 5.9% · OPM 6.7% 57% evidence | 9.8/20 P/E 40.8× · PEG — 15% evidence | 7.1/20 RS sector -21.1% · RS bench -6.7% · 1Y -24.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 10.7 + 9.8 + 7.1 = 50.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Twilio Inc.TWLO | 49.9/100Mixed-negative evidence64% evidence | TURNING | 18.1/35 Revenue 17.8% · PAT — · OPM change 2.6 pp 62% evidence | 7.3/25 ROCE 0.9% · OPM 5.6% 76% evidence | 10.4/20 P/E 28.7× · PEG — 15% evidence | 14.1/20 RS sector 21.6% · RS bench 42.4% · 1Y 124.3%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 7.3 + 10.4 + 14.1 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Samsara Inc.IOT | 49.8/100Mixed-negative evidence64% evidence | BREAKING OUT | 24.4/35 Revenue 29.6% · PAT — · OPM change 10.6 pp 62% evidence | 6.0/25 ROCE -0.7% · OPM 1.5% 76% evidence | 8.6/20 P/E 308.9× · PEG — 15% evidence | 10.8/20 RS sector -7.3% · RS bench 9.2% · 1Y 1.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 6 + 8.6 + 10.8 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17DigitalOcean Holdings, Inc.DOCN | 49.8/100Thin evidence · provisional56% evidence | ASLEEP | 17.3/35 Revenue 17.7% · PAT 100% · OPM change -3.7 pp 53% evidence | 11.2/25 ROCE 2.2% · OPM 14.2% 57% evidence | 10.1/20 P/E 37.5× · PEG — 15% evidence | 11.2/20 RS sector 13.7% · RS bench 33.5% · 1Y 238.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 11.2 + 10.1 + 11.2 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Check Point Software Technologies Ltd.CHKP | 45.1/100Thin evidence · provisional56% evidence | TURNING | 14.8/35 Revenue — · PAT — · OPM change -3 pp 39% evidence | 14.2/25 ROCE 3.8% · OPM 27.7% 76% evidence | 11.2/20 P/E 13.5× · PEG — 15% evidence | 4.9/20 RS sector -31.8% · RS bench -18.9% · 1Y -30.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 14.2 + 11.2 + 4.9 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Cloudflare, Inc.NET | 43.5/100Mixed-negative evidence61% evidence | LEADER | 12.7/35 Revenue 33.6% · PAT — · OPM change -16.5 pp 62% evidence | 4.0/25 ROCE -4.8% · OPM -29.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.8/20 RS sector 16.1% · RS bench 36.3% · 1Y 43.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 4 + 10 + 16.8 = 43.5 · Decision use: Price leads the evidence: RS versus the benchmark is 36.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20MongoDB, Inc.MDB | 42.6/100Mixed-negative evidence61% evidence | LEADER | 20.9/35 Revenue 23.7% · PAT — · OPM change 6.2 pp 62% evidence | 5.4/25 ROCE -0.8% · OPM -3.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.3/20 RS sector -12.6% · RS bench 3.2% · 1Y 16.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 5.4 + 10 + 6.3 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Palo Alto Networks, Inc.PANW | 42.1/100Mixed-negative evidence75% evidence | LEADER | 8.5/35 Revenue 24.5% · PAT -72.9% · OPM change -8.5 pp 95% evidence | 9.3/25 ROCE 2.1% · OPM 5% 76% evidence | 9.1/20 P/E 96.2× · PEG — 15% evidence | 15.2/20 RS sector 30.6% · RS bench 52% · 1Y 80.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 8.5 + 9.3 + 9.1 + 15.2 = 42.1 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Akamai Technologies, Inc.AKAM | 40.8/100Mixed-negative evidence66% evidence | ASLEEP | 12.7/35 Revenue 6.1% · PAT -4% · OPM change -4.5 pp 53% evidence | 11.5/25 ROCE 1.2% · OPM 10.7% 57% evidence | 14.0/20 P/E 38.7× · PEG 0.7 65% evidence | 2.6/20 RS sector -20.4% · RS bench -5.6% · 1Y 37%4 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 11.5 + 14 + 2.6 = 40.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 23Zscaler, Inc.ZS | 39.8/100Mixed-negative evidence61% evidence | TURNING | 17.5/35 Revenue 24.6% · PAT — · OPM change 0.2 pp 62% evidence | 5.0/25 ROCE -0.9% · OPM -3.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.3/20 RS sector -22.1% · RS bench -8.2% · 1Y -34.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 5 + 10 + 7.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24VeriSign, Inc.this pageVRSN | 37.0/100Mixed-negative evidence81% evidence | TURNING | 10.5/35 Revenue 6.9% · PAT 6.5% · OPM change -0.3 pp 83% evidence | 10.2/25 ROCE -1203.5% · OPM 68.2% 76% evidence | 7.6/20 P/E 27× · PEG 2.65 65% evidence | 8.7/20 RS sector -9.9% · RS bench 6.5% · 1Y 5.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 10.2 + 7.6 + 8.7 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25CoreWeave, Inc.CRWV | 33.6/100Adverse evidence61% evidence | ASLEEP | 16.4/35 Revenue 100% · PAT — · OPM change -3.5 pp 62% evidence | 5.8/25 ROCE -0.1% · OPM -1.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.4/20 RS sector -31.1% · RS bench -18.4% · 1Y -33.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 5.8 + 10 + 1.4 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Block, Inc.XYZ | 32.0/100Adverse evidence71% evidence | FADING | 9.0/35 Revenue 5.1% · PAT -87.9% · OPM change -1.2 pp 83% evidence | 8.8/25 ROCE 1.6% · OPM 6.8% 76% evidence | 8.8/20 P/E 135.7× · PEG — 15% evidence | 5.4/20 RS sector -12.7% · RS bench 2.9% · 1Y -0.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 8.8 + 8.8 + 5.4 = 32 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Synopsys, Inc.SNPS | 31.4/100Adverse evidence81% evidence | BASING | 12.2/35 Revenue 39.5% · PAT -41.8% · OPM change -18.2 pp 83% evidence | 9.7/25 ROCE 0.4% · OPM 5.3% 76% evidence | 8.5/20 P/E 111.7× · PEG 1.78 65% evidence | 1.0/20 RS sector -32.8% · RS bench -20.1% · 1Y -23.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 9.7 + 8.5 + 1 = 31.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Cerebras Systems Inc.CBRS | 43.7/100Thin evidence · provisional41% evidence | ASLEEP | 20.1/35 Revenue 90.5% · PAT — · OPM change -209.7 pp 62% evidence | 3.6/25 ROCE -9.5% · OPM -265% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 6 weeks ahead 0% evidence |
| Exact sum: 20.1 + 3.6 + 10 + 10 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is VeriSign, Inc.'s stock price today?
VeriSign, Inc. trades at $298, +5.7% over the past year. The company is valued at $27.0 B. The stock sits at 88% of its 52-week range of $216–$310, +13.4% versus its 200-day average. On the tape, the price is topping out, 11 weeks in. — as of 17 September 2026.
What were VeriSign, Inc.'s latest quarterly results?
VeriSign, Inc. reported revenue of $0.4 B and net profit of $0.2 B for the Jun 26 quarter. Revenue rose 4.9% and profit rose 4.8% year on year. Earnings per share were $2.38. The operating margin was 69.8%, 1.5 pp higher than a year earlier. — as of 17 September 2026.
What is VeriSign, Inc.'s revenue?
VeriSign, Inc. reported revenue of $0.4 B in the Jun 26 quarter, +4.9% year on year. For the full FY25 fiscal year, revenue was $1.7 B (+6.4%). Over the last 4 years revenue compounded at 5.7% a year. — as of 17 September 2026.
What is VeriSign, Inc.'s profit?
VeriSign, Inc. earned $0.2 B of net profit in the Jun 26 quarter, +4.8% year on year — the 6th straight quarter of growth. Full-year FY25 profit was $0.8 B. The operating margin ran 69.8% in the latest quarter. — as of 17 September 2026.
What is VeriSign, Inc.'s market cap?
VeriSign, Inc.'s market capitalisation is $27.0 B at a stock price of $298. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is VeriSign, Inc.'s P/E ratio?
VeriSign, Inc. trades at a P/E of 32.3×, at the 80th percentile of its own 5-year range, against a long-run median of 28.7×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does VeriSign, Inc. pay a dividend?
Yes — VeriSign, Inc. declared $0.81 per share for Jun 26, and $3.16 per share across the last four reported quarters. — as of 17 September 2026.
What is VeriSign, Inc.'s dividend per share?
VeriSign, Inc.'s most recently declared dividend is $0.81 per share for Jun 26, giving $3.16 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is VeriSign, Inc.'s dividend yield?
VeriSign, Inc.'s trailing dividend yield is 1.06%: $3.16 declared per share across the last four reported quarters, against a share price of $298. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is VeriSign, Inc. overvalued?
On its own history, VeriSign, Inc. looks expensive: its P/E of 32.3× sits at the 80th percentile of its 5-year range (long-run median 28.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is VeriSign, Inc. growing?
Yes — VeriSign, Inc. is growing: latest-quarter revenue +4.9% year on year, profit +4.8%, and the margin +1.5 pp at 69.8%. The 4-year compound rates are 5.7% (revenue) and 1.6% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is VeriSign, Inc. performing?
VeriSign, Inc. is topping out, 11 weeks in. Its latest quarter's revenue rose 4.9% and profit rose 4.8% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is VeriSign, Inc. in?
Mixed — the growth curves are steadily positive, but no return curve is held to confirm the Consistent bar. The read comes from the last 12 quarters of growth (revenue growth +6.9% latest, profit growth +6.3% latest, eps growth +10.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is VeriSign, Inc. in an uptrend?
It is stalling — the price is topping out (week 11 of stage 3), trading +13.4% versus its 200-day average and at 88% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is VeriSign, Inc. beating the market?
On recent form, yes — VeriSign, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +249% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will VeriSign, Inc.'s stock price go up?
This page publishes no price forecast for VeriSign, Inc. What it measures instead: the stock price is $298, the price is topping out 11 weeks in. Its P/E of 32.3× sits at the 80th percentile of its own 5-year range. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against VeriSign, Inc.?
No — short interest is 1.9% of VeriSign, Inc.'s tradable float, about 2.2 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
What is VeriSign, Inc.'s capex?
VeriSign, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is VeriSign, Inc.'s cash flow?
VeriSign, Inc. generated $1.1 B of operating cash flow in FY25 and $1.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.8 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is VeriSign, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 116% of VeriSign, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $1.1 B against reported profit of $0.8 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is VeriSign, Inc.?
On the balance sheet, the Z-score reads −2.68 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 17 September 2026.
Where is VeriSign, Inc. in its business cycle?
VeriSign, Inc.'s FY25 operating margin was 67.5%, against a 5-year band of 65.4%–67.9%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 69.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the VeriSign, Inc. story?
The sharpest disagreement: the engine is strong, but at the 80th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is VeriSign, Inc. a stock worth studying right now?
This is not investment advice. The machine read: VeriSign, Inc.'s balance sheet is under water — net worth is negative, so it owes more than it owns. This is a distressed, high-risk situation — the equity can be wiped by dilution or restructuring before operations recover. Not a value setup. The sharpest open question: whether the business can earn its way back to positive equity before dilution or restructuring gets there first. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!